Introduction
Current ideological frameworks for the pathogenesis of prostate cancer (Pca) emphasize the roles of precursor lesions such as prostatic intraepithelial neoplasia (PIN), proliferative inflammatory atrophy (PIA) and tissue hypoxia. Alternative theories suggest that prostate stem cells function as reservoirs of disease. Research has focused on identifying potential molecular and genetic markers, which may help to clarify and predict the natural history of PCa: thus helping to identify those suitable for active surveillance [1] . A number of potential diagnostic, prognostic and surveillance markers have been identified (Table 1) .
Developments in molecular technology have helped to identify and alter the expression of these genes and the related markers. Techniques such as fluorescence-activated cell sorting, fluorescence in situ hybridization, reverse trans cri ption polymerase chain reaction and proteomics have improved sensitivity, facilitating the detection of smaller groups of prostate cells and markers. The identification of many markers still relies on tissue sampling, which is invasive and susceptible to sampling error. Urine and serum samples are safer, more acceptable alternatives and have been analysed using deoxyribonucleic acid (DNA)/ribonucleic acid (RNA)-based assays. However, urine and serum samples may have lower sensitivities because early well-differentiated PCa is less likely to be present [21] . In metastatic PCa, > 5 cells per 7.5 mL of blood are detectable, setting a minimum target for molecular assays [20] . The role of seminal plasma as a rich source of markers has also been reviewed, but limited studies exist because of difficulties in sampling and tolerance [21] . Difficulties in obtaining sufficient amounts of high-quality ribonucleic acid for microarrays have also [2] . Alpha methlyacyl coenzyme A racemase protein voided in urine. Involved in fatty acid β-oxidation. Androgenindependent function as promoter of PCa [6] . Androgen receptor, nuclear transcription factor mediates steroid hormones and stromal cell growth. AR activation in luminal cells suppresses growth [8] .
B-cell CLL/lymphoma 2, antiapoptotic protein found in basal cells and stem cells [2] . Loss of expression linked to PIN, progression and androgen independence [11] . Breast cancer type 2 susceptibility protein, tumour suppressor gene, predisposes to Pca, chromosome 13q. Chorionic gonadotropin alpha, neuroendocrine prehormone peptide. Unclear mechanism of action. Role in cell cycle from G1-to S-phase. Cell adhesion molecule. Downregulation/loss associated with invasion and metastasis. Activation associated with proliferation, malignant transformation, relapse, progression and androgen independence [4] . Epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (Her2). Mouse engrailed-2 gene. Homoeobox-containing transcription factor/candidate oncogene, overexpressed in aggressive HRPC/PCa. May be positively modulated by PAX2 [17] .
Selected literature PTEN null mice develop high-grade PCa and metastasis [3] . Genetic PTEN alteration seen in 10% primary PCa, >30% metastases, PTEN loss induces p53 senescence [4] . Possible use as gene therapy vector [5] . 100% sensitive, 58% specific. Small study [7] . Histopathological biomarker [6] .
Stimulates early PCa growth, gene amplification in 30% AI tumours [4] . AR mutations rare in untreated PCa [9] . Vorinostat (histone deacetylase inhibitor) may reduce AR expression acting synergistically with bicaltamide (AR antagonist) to inhibit PCa [10] . Antisense oligonucleotides (Oblimersen) against Bcl-2 delay progression, improves chemo-sensitivity. Doce taxel combination trial underway (NCT00085228) [12, 13] .
< 5% Familial/young-onset cases diagnosed < 55 years old [14] . Limited use and reproducibility. Correlation with time to androgen independence and adverse outcome [6] . Upregulation may be associated with androgen independence and poor prognosis [8] .
Close univarate T and M stage and survival significance [8] .
Higher levels in PCa than BPH [15] . Monoclonal antibodies directed against specific binding domains, anti-EGFR, e.g. cetuximab, anti-HER2, e.g. trastuzumab [16] . Lack of significant role in PCa [12] . En-2 downregulation by siRNA decreases PAX2 and decreases PCa cell proliferation [17] . PAX2 has been postulated as essential for PCa cell survival [18] . [23, 24] . Encodes PSA, a kallikrein-related peptidase (serine protease subgroup) on chromosome 19 [12] . Encodes hK2, a kalikrein-related peptidase (serine protease subgroup) on chromosome 19. Serum levels 1% of PSA and undetectable in healthy males [25, 26] . Mindbomb homolog 1, monoclonal antibody and cell proliferation marker by Ki-67 antigen recognition. Microseminoprotein, beta-, encodes PSP94, immunoglo bulin-binding factor synthesized in prostatic epithelial cells [25] . NK3 transcription factor related, locus 1, homoeobox tumour suppressor gene, exclusive to prostate, undergoes epigenic inactivation [4] Ch 8p12-21 [28] . Neuron-specific enolase, neuroendocrine cell product.
Selected literature
No link to Gleeson score. Reported positive in BPH pts who subsequently developed PCa. EPCA 1 and 2, 92% sensitive, 94% specific. EPCA2 distinguishes localized vs. extracapsular disease (P < 0.0001) [cited in [6] . Awaiting larger trials [19] . Close univarate M stage and survival significance [8] .
Linked to high-grade PCa development [20] . GSTP-1 hypermethylation: > 90% PCa, > 70% PIN, rare in benign disease. Urinary marker, may need prostatic massage. Small study. Diagnostic performance improved as a part of multiple gene panel [6] . Elevated levels related to advanced disease but not prognostic. Possible role as combination markers [6] . Combination rV-PSA and fowl pox primed rF-PSA vaccines trialled. Phase II studies: median time to PSA progression increased (9.2-18.2 months) (study ECOG7897). Phase III PARADIGM trial underway [12] .
hK2 with free and total PSA significantly improved diagnostic sensitivity/specificity . Predicts prostate biopsy outcome (P < 0.001). Role in predicting recurrence/ progression [6 , 25] .
Close univarate T, M stage and survival significance [8] .
Loss of PSP94 expression associated with recurrence after radical prostatectomy [27] .
Increasing loss of protein expression in hormonerefractory and metastatic disease [29] .
Unknown paracrine/autocrine function [6] . Tumour suppressor gene allows DNA repair/cell apoptosis in cellular stress conditions [8] . Ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent). Candidate tumour suppressor gene product [42] implicated in viral defence, regulates cell proliferation and apoptosis via an interferon pathway Ch 1q23-25 [43] . Transforming growth factor. pleiotrophic growth factor known to promote stem cell quiescence [45] . Transmembrane protease, serine 2 fusion gene (Ch 21),
upregulates ETS target genes controlling cell proliferation, differentiation, apoptosis and transformation [2, 4] . Testosterone is essential for prostatic development and maintenance. Oestrogens are associated with low risk of PCa [6] .
Urokinase plasminogen activator/cell surface receptor. Role in basement membrane/extracellular matrix degradation and metastases [6] .
Selected literature Functional loss linked to progression and AI [4, 30] . PIA association [31] . Gene therapy target with recombinant adenovirus [11] . APC8015 autologous vaccine. Phase I/II trials in HRPC. 31 patients, 38% developed immune response, three had PSA reduction > 50%. Overall survival increased 4.5 months (P = 0.01). Phase III IMPACT trial ongoing [12] . First biopsy, PCA3 sensitivity 50%, specificity 77% [34] . Repeat biopsy, PCA3 score > 35, sensitivity 57% and specificity 73% [35] . Predictive of extracapsular extension and tumour volume, 94% specific, 80% positive predictive value [36] . DCVax-prostate vaccine target. Phase I/II trial underway [12] .
Correlated to Gleason score, advanced stage, metastasis and AI (cited in [6] ]). High independent prognostic value and specificity [38] .
Less significant in PCa, uncommon mutation in early PCa [39] . Independently prognostic in late-stage PCa [40] .
Concomitant homozygous PTEN-p53 inactivation lead to
PCa lethality in mice [41] . RNasel variant Arg462Gln significantly associated with PCa (P = 0.007). Mutated allele found in 60% of the men in the study group. 50% greater risk in heterozygous carriers [44] . Does not accurately distinguish PCa and benign disease.
May have a role in progression and metastasis [6] . May be an early marker, as seen in 20% of PIN lesions [46] . High testosterone levels=lower PCa risk (non-Gleason > 7, stage 4, N+, M+) (P = 0.003). Serum testosterone < 300 ng per 100 mL predictor of PSA failure after radical prostatectomy. High levels of SHBG predict extracapsular extension (P = 0.006) [6] . u-PA/u-PAR correlated to tumour stage and grade and inversely to androgen receptor status [6] . been overcome [16, 47] . Notably, multiple marker arrays may also improve detection; Glutathione-S-transferase P1 (GSTP-1) has been used in a four-gene panel (p16/ARF/ MGMT/GSTP-1) in 52 PCa patients, resulting in 87% sensitivity and 100% specificity. These data need to be reproduced in large-scale randomized studies [48] .
Genetics
Familial and epidemiological studies have supported the concept of a genetic predisposition to PCa and have helped to clarify susceptible loci [14, 28, 49, 50] . Some studies have focused on specific groups such as Ashkenazi Jews, but to date no single gene has reproducibly been found to be responsible for PCa, reflecting the multifocal and heterogenic nature of PCa [4, 51] . Familial studies have shown the relative risks of PCa to be 2.0 and 1.7 in first-and second-degree relatives, respectively, with the risk increasing to 8.8 when first-and second-degree relatives are both afflicted [49, 52] . A recent genome-wide association study identified several loci (chromosomes 3, 6, 7, 10, 11, 19 and X) associated with PCa [25] . The previously known 8q24 and17q loci were also confirmed, along with the identification of three new candidate susceptibility genes (MSMB, LMTK2, KLK3) [25] . Several groups have identified links to other loci; however, reproducibility between data sets has been limited. Nonetheless, common loci have been found on chromosomes 1, 8p12-22, 17, 19 and 22 [4, 50] . Genetic changes in PIN have also been identified and implicated in PCa pathogenesis, with 8p12-22 loss of heterozygosity seen in 63% of PIN lesions [53] . Viral DNA expression upon genomic screening of PCa spe ci mens has also been reported [54] .
Proteomics
Current research has focused on the mass identification of proteins. Proteomics has resulted in the ability to rapidly process large numbers of clinical samples, potentially deeming it to be a highly sensitive diagnostic, surveillance and prognostic tool [55] . Proteomics uses surface-enhanced laser desorption/ionization time-of-flight mass spectrometry with selective primed surface arrays [55] . Notably, proteomic pattern analysis has correctly identified up to 95% of PCa and 78% of benign samples [56] . Prostate biopsies could thus be avoided in men with PSA ranges from 2.5 to 15 ng mL -1 without missing any instances of PCa [57] . Nonetheless, several problems need to be overcome, including artefacts, sample errors, storage and collection techniques; proteomic profiles may vary at different stages of PCa, resulting in inconsistency [55] .
Hypoxia, PIA and PIN
One proposed mechanism for prostate carcinogenesis is that genomic DNA may undergo genotoxic stress such as occurs in hypoxia or inflammation. This may occur under normal cellular conditions or secondary to external insults, resulting in activation of cellular checkpoint cascades capable of repair, cell-cycle arrest or apoptosis [4] . Abnormalities in this control mechanism have been implicated in progression to PCa, including defects in the p53 response and lack of DNA damage checkpoint enforcement by Wee1A (a G2/M regulator) [58, 59] .
Tissue hypoxia is detectable in 30%-90% of PCa samples, and its role in PCa microenvironments has been reviewed [60] . Hypoxia may arise when tumour growth surpasses the vascular supply provided by angiogenic growth, and it has been implicated as a prognostic factor linked to androgen independence and chemo/radiotherapy resistance. Hypoxia may alter cell-cycle checkpoints and DNA repair (leading to genetic instability), up-regulate VEGF/HIF-1 expression (promoting angiogenesis and metastasis) and reduce apoptosis through p53-mutated cells [60] . Studies have also shown that antiandrogens improve tissue oxygenation by reducing angiogenesis [60] .
PIN and PIA are found in PCa specimens and are thought to be precursor lesions, with PIA found to merge with areas of PIN [61] . PIA is postulated as a link between prostatitis and PIN and is common in the peripheral zone of the prostate [62] . A number of studies support the theory of PIA as a PCa precursor. The odds ratio of PCa in prostatitis is 1.7, with a relative risk of 2.5 for bacterial prostatitis [63] . PIA is thought to be a regenerative lesion associated with a low apoptotic rate and elevated Bcl-2 expression [31] . Another study has detected bacterial DNA sequences in 19.6% of patients with PCa [64] . Inflammation is thought to produce free radicals and oxida tive stress, inducing protein, tissue and vascular damage leading to PIA. Anti-inflammatory agents are associated with a > 50% reduction in PCa risk, and COX-2 inhibitors have been shown to slow progression and recurrence of PCa [12] . Presently, COX-2 inhibitors have been withdrawn from the market owing to cardiovascular side effects. Other antiinflammatory agents, such as epigallocatechin-3-gallate found in green tea, may also play a chemo-preventive role [65] . These observations suggest poten tial genetic targets for prevention and treatment. Potential markers involved in the susceptibility of the prostate to infection include macrophage scavenger receptor 1, TOLL-like receptor-4 and 2'-5'-oligoadenylate-dependent RNasel (RNasel) and the loss of glutathione S-transferase (a detoxifying enzyme linked to genomic instability and damage) [43] .
Stem cells
The cancer stem cell theory, which proposes that PCa [19, 66] . This theory is supported by recent observations. In acute myelogenous leukaemia, only minor subpopulations of cells have been shown to be capable of self-renewal, disease initiation and propagation when transplanted into im mune-deficient mice [67] . Clonality has also shown the ability of these cells to differentiate into the various original leukaemic cells. In the prostate, cyclical atrophy and regeneration of rodent prostate glands with intermittent androgen deprivation have been described, showing the capacity for self-renewal and suggesting the presence of PSCs [2] . In addition to these PSCs being androgen independent, cancer stem cells have been shown to be relatively chemo/radiotherapy insensitive, hence acting as a possible reservoir for recurrent and androgen-independent (hormone-resistant PCa [HRPC]) disease [20, 68, 69] . Four cellular types exist within the prostate, which are identifiable by specific markers (basal cells, transient amplifying cells, luminal and neuroendocrine cells) [4] . PSCs are hypothesized to reside in the basal cell layer and may produce intermediate transient amplifying cells, which exhibit both luminal and basal cell markers. The neuroendocrine cell lineage is still unknown, but may arise from PSCs [2, 70] . Previous studies cited by the authors support this concept owing to the absence of a prostate in mice null for basal layer marker p63. Stem cell markers have also been identified in human and murine prostatic epithelial cells (Sca-1, CD133, α2β1, integrin, CD44, Oct4, Nanog, breast cancer resistance protein and SOX2) [4, 19, 20] ). PSC research is in its infancy, with stem cell culture reported to be demanding, relatively unproductive and subject to variation in different environments/culture media [71] . PSCs are also rare in circulating blood, and adequate sampling requires biopsy or bone marrow aspiration [20] . However, therapies directed at selectively targeting PSC surface markers and their signalling pathways may offer a novel and highly specific treatment approach to PCa. The challenge will be to ensure tissue and organ specificity. Finally, Hedgehog pathway inhibitors have been shown to halt growth of PCa in murine models [2] .
Conclusion
The genetic and molecular basis of PCa is complex; however, technological advances have increased our know ledge in this field. The identification of multiple genetic and biological markers has reinforced the concept of a 'multi-hit theory' for PCa, with some patients being genetically predisposed. Other genetic loci may only be altered under specific dietary or environmental conditions. Bacterial and viral infectious triggers may also be involved. PSA is the current mainstay for diagnosis and prognosis, but has a sensitivity of 20% and a specificity of 80% (PSA range, 4-10 ng mL -1 ) [72] . Biomarkers for risk stratification, prediction of invasion and metastases are emerging, with multiple marker assays potentially offering improved diagnostic benefits. New markers such as PCA3, AMACR, EPCA, GSTP1, RNASEL and hK2 offer the potential to improve sensitivity and specificity, with some now having achieved commercial and clinical acceptance.
